Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?

Journal of Clinical Investigation

Volumn 99, Issue 6, 1997, Pages 1173-1178

  Saas, Philippe ^a   Walker, Paul R ^a   Hahne, Michael ^b   Quiquerez, Anne Lise ^a   Schnuriger, Valérie ^a   Perrin, Gaëlle ^a   French, Lars ^c   Van Meir, Erwin G ^d   De Tribolet, Nicolas ^d   Tschopp, Jürg ^b   Dietrich, Pierre Yves ^a,e  

^a University Hospital   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Lab d'Immunologie des Tumeurs   (Switzerland)

Author keywords

apoptosis; CD95; central nervous system; glioma; immune tolerance

Indexed keywords

FAS ANTIGEN; LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTOMA; CELL CONTACT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030895084     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119273     Document Type: Article

References (35)

1. Barker, C.F., and R.E. Billingham. 1977. Immunologically privileged sites. Adv. Immunol. 25:1-54.
2. Fabry, Z., C.S. Raine, and M.N. Hart. 1994. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today. 15:218-224.
3. Cserr, H.F., and P.M. Knopf. 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today. 13: 507-512.
4. Fontana, A., F. Kristensen, R. Dubs, D. Gemsa, and E. Weber. 1982. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J. Immunol. 129:2413-2419.
5. 2. J. Immunol. 143:3222-3229.
6. 8+ T cells. J. Immunol. 155:609-618.
7. 2, decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J. Immunol. 155:325-332.
8. Kuppner, M.C., M.F. Hamou, and N. de Tribolet. 1988. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 48:6926-6932.
9. Rossi, M.L., J.T. Hughes, M.M. Esiri, H.B. Coakham, and D. Brownell. 1987. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol. 74:269-277.
10. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
11. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science (Wash. DC). 267:1449-1456.
12. Lynch, D.H., F. Ramsdell, and M.R. Alderson. 1995. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today. 16:569-574.
13. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature (Lond.). 370:650-652.
14. Kägi, D., F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hentgartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science (Wash. DC). 265:528-530.
15. Bellgrau, D., D. Gold., H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature (Lond.). 377:630-632.
16. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (Wash. DC). 270:1189-1192.
17. Van Meir, E., Y. Sawamura, A.C. Diserens, M.F. Hamou, and N. de Tribolet. 1990. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50:6683-6688.
18. Serano, R.D., C.N. Pegram, and D.D. Bigner. 1980. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol. 51:53-64.
19. Kleihues, P., P.C. Burger, and B.W. Scheithauer. 1993. The new WHO classification of brain tumours. Brain Pathol. 3:255-268.
20. Hahne, M., M.C. Peitsch, M. Irmler, M. Schröter, B. Lowin, M. Rousseau, C. Bron, T. Renno, L. French, and J. Tschopp. 1995. Characterization of the non-functional Fas ligand of gld mice. Int. Immunol. 7:1381-1386.
21. Takahashi, T., M. Tanaka, J. Inazawa, T. Abe, T. Suda, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567-1574.
22. Sarmiento, M., D.P. Dialynas, D.W. Lancki, K.A. Wall, M.I. Lorber, M.R. Loken, and M.W. Fitch. 1982. Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis. Immunol. Rev. 68:135-169.
23. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshimo, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-1783.
24. Bordier, C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 256:1604-1607.
25. Hahne, M., T. Renno, M. Schroeter, M. Irmler, L. French, T. Bornand, H.R. MacDonald, and J. Tschopp. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721-724.
26. Matzinger, P. 1991. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods. 145:185-192.
27. Suda, T., and S. Nagata. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179:873-879.
28. Weller, M., K. Frei, P. Groscurth, P.H. Krammer, Y. Yonekawa, and A. Fontana. 1994. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94:954-964.
29. French, L.E., M. Hahne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Müller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133:335-343.
30. Glass, A., C.M. Walsh, D.H. Lynch, and W.R. Clark. 1996. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol. 156:3638-3644.
31. Iwai, K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. Yachie, H. Seki, and N. Taniguchi. 1994. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 84:1201-1208.
32. 8+ T lymphocytes. Inhibition by transforming growth factor-β. J. Immunol. 146:3289-3297.
33. Streilein, J.W. 1995. Unraveling immune privilege. Science (Wash. DC). 270:1158-1159.
34. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
35. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash. DC). 274:1363-1366.